NAGE Niagen Bioscience Inc. presents a perplexing valuation scenario. Despite a Forward P/E of 9.93 suggesting potential undervaluation, the stock’s DCF Value is alarmingly negative, indicating possible overvaluation or flawed projections. The Graham Number further supports this, being significantly lower than the snapshot price. However, the Altman Z-score of 6.63 signals robust financial health, reducing bankruptcy risk. The Earnings Yield of 5.59% implies moderate income generation relative to price, but the market may be mispricing growth prospects.